BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357]
URL: https://www.wjgnet.com/1007-9327/full/v18/i12/1357.htm
Number Citing Articles
1
Benjamin A. Weinberg, Michael J. Pishvaian. Current and Emerging Therapies in Pancreatic Cancer2018; : 281 doi: 10.1007/978-3-319-58256-6_16
2
Constantin Maier-Stocker, Michael Bitzer, Nisar P. Malek, Ruben R. Plentz. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohortScandinavian Journal of Gastroenterology 2014; 49(12): 1480 doi: 10.3109/00365521.2014.978816
3
Lauren A. Mauro, Joseph M. Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology2014; : 1397 doi: 10.1016/B978-1-4557-2865-7.00081-3
4
Hideyuki Nishiofuku, Toshihiro Tanaka, Nagaaki Marugami, Masayuki Sho, Takahiro Akahori, Yoshiyuki Nakajima, Kimihiko Kichikawa. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancerEuropean Radiology 2016; 26(6): 1835 doi: 10.1007/s00330-015-3999-2
5
Hiroshi Yoneyama, Asako Takizawa-Hashimoto, Osamu Takeuchi, Yukiko Watanabe, Koichiro Atsuda, Fumiki Asanuma, Yoshinori Yamada, Yukio Suzuki. Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clonesAnti-Cancer Drugs 2015; 26(1): 90 doi: 10.1097/CAD.0000000000000165
6
Matthieu Sarabi, Laetitia Mais, Nadia Oussaid, Françoise Desseigne, Pierre Guibert, Christelle De La Fouchardiere. Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinomaOncology Letters 2017; 13(6): 4917 doi: 10.3892/ol.2017.6061
7
Alexander Kleger, Thomas Seufferlein. Erkrankungen des Pankreas2013; : 394 doi: 10.1007/978-3-642-37964-2_74
8
A. Brú, R. Bosch, M. V. Céspedes, S. Carmona-Güedes, E. Pascual, I. Brú, J. C. Souto. Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancerScientific Reports 2019; 9(1) doi: 10.1038/s41598-019-39805-y
9
Terumasa HISANO, Takashi FUJIYAMA, Rie SUGIMOTO, Yukihiko OKUMURA, Masayuki FURUKAWA. A study on the effectiveness of additional chemotherapy in patients with advanced pancreatic cancer that have become resistant to the treatment of both S-1 and gemcitabineSuizo 2013; 28(1): 56 doi: 10.2958/suizo.28.56
10
Ron Epelbaum, Einat Shacham-Shmueli, Baruch Klein, Abed Agbarya, Baruch Brenner, Ronen Brenner, Eliahu Gez, Talia Golan, Ayala Hubert, Ofer Purim, Mark Temper, Ella Tepper, Andreas Voss, Kenneth Russell, Addie Dvir, Lior Soussan-Gutman, Salomon M. Stemmer, Ravit Geva. Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter StudyBioMed Research International 2015; 2015: 1 doi: 10.1155/2015/681653
11
Ana De Jesus-Acosta, Amol Narang, Lauren Mauro, Joseph Herman, Elizabeth M. Jaffee, Daniel A. Laheru. Abeloff's Clinical Oncology2020; : 1342 doi: 10.1016/B978-0-323-47674-4.00078-5
12
Hend Ahmed El-Hadaad, Hanan Ahmed Wahba. Oxaliplatin Plus 5-Fluorouracil and Folinic Acid (OFF) in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II StudyJournal of Gastrointestinal Cancer 2013; 44(3): 313 doi: 10.1007/s12029-013-9495-5